Principal Investigators

    Prof Donald Weaver


    Treventis Corporation

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    Design and Optimisation of New Chemical Entities that Prevent the Neurotoxic Oligomerization and Misfolding of both beta-amyloid and tau Proteins: A Disease Modifying Therapeutics Approach for Alzheimer's Dementia

    Source of funding information

    The Wellcome Trust

    Total sum awarded (Euro)

    € 3,601,588

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    Numerous studies support a causative role for b-amyloid (A ) and tau in the aetiopathogenesis of Alzheimer’s disease (AD).1,2 These proteins tend to abnormally clump ,3,4 and such protein misfolding processes give rise to neurotoxic aggregates of b-amyloid ( plaques ) and tau ( tangles ) the pathological hallmarks of AD.5 In vitro studies have verified that Ab is significantly neurotoxic when in small aggregates (dimers, trimers and other oligomers).6,7,8 Since diseasemodifying (in preference to merely symptomatic) drugs represent the most desirable therapeutic approach to AD,9 protein misfolding of A and tau represents a leading target in the rational design of a disease-modifying drug.1

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: United Kingdom
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF